-

BioTek reMEDys to Attend Immunoglobulin National Society Meeting

NEW CASTLE, Del.--(BUSINESS WIRE)--As part of its commitment to expand upon health literacy and explore best practices in the immunoglobulin therapy space, BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, has sent its team of Immunoglobulin National Society (IgNS) certified pharmacists to this week’s IgNS 2023 annual national conference in Denver for the latest clinical education and practice advancements with patients and colleagues.

The Immunoglobulin National Society is a professional organization dedicated to the advancement of immunoglobulin therapy practice, across clinical indications and areas of practice. This year’s in-person conference, which started today and will run through October 8th, is being headlined by renowned keynote speakers and invited lecturers, thought-provoking sessions, and in-depth educational and networking events.

The mission of IgNS is to:

  • Develop and sustain evidence-based Ig Therapy standards of practice
  • Provide systematic, multi-disciplinary education
  • Support best practices through professional certification
  • Promote patient-centric initiatives and outcomes

“We’re proud to be long-time supporters of the Immunoglobulin National Society and are excited to be participating this year by sending our pharmacist colleagues to the annual event,” said BioTek reMEDys’ CEO and founder Chaitanya Gadde. “Immunoglobulin therapy is one of the most complex fields of clinical practice, requiring clinicians to possess highly-specialized expertise and skills. As such, IgNS certification and the programs and events the organization offers are critically important so that we as a healthcare community can provide patients with the knowledge, skills, and overall clinical competence of nurses and pharmacists managing and administering Ig therapy.”

BioTek reMEDys is a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases. Through supply chain management, innovative technology and trained specialty pharmacists, BioTek reMEDys is able to deliver superior service at a lower cost. The company bridges the gap between managed care, physicians and patients by facilitating the authorization, procurement and administration of specialty medications and infusions. BioTek reMEDys provides high-touch therapies, biologics and pharmaceuticals to support treatment for patients with rare diseases and chronic conditions, ensuring the highest quality of care. For information visit www.biotekrx.com.

Contacts

Media Contact:
Paul Williams
paul@medialinecommunications.com
310/569-0023

BioTek reMEDys


Release Versions

Contacts

Media Contact:
Paul Williams
paul@medialinecommunications.com
310/569-0023

Social Media Profiles
More News From BioTek reMEDys

BioTek reMEDys Encourages Education and Awareness for Autoinflammatory Conditions

NEW CASTLE, Del.--(BUSINESS WIRE)--BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, is publicly calling for year-round enhanced education and awareness of these rare diseases and conditions. Autoinflammatory diseases refer to problems with the innate immune system’s reactions. Immune cells target the body’s own healthy tissues by mistake, signaling the body to attack them. This can cause intense episodes of inf...

BioTek reMEDys Celebrates the Work of Collaborating Healthcare Professionals During National Interprofessional Healthcare Month

NEW CASTLE, Del.--(BUSINESS WIRE)--In recognition of National Interprofessional Healthcare Month, BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, is publicly calling for awareness of safe medication use for patients with rare diseases and conditions, while celebrating the critical contributions and collaborative spirit of healthcare professionals nationwide, applauding the efforts of those who impact the patie...

BioTek reMEDys Names Neal Fitzpatrick Chief Strategy Officer

NEW CASTLE, Del.--(BUSINESS WIRE)--BioTek reMEDys, a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases, has named Neal C. Fitzpatrick as its Chief Strategy Officer. Fitzpatrick recently served as Chief Commercial Officer at a biotech company, charged with leading the organization through a period of high growth. Before this, he served as Vice-President of Sales at ADMA Biologics, where he repositioned an essential product from hos...
Back to Newsroom